MDaudit to acquire Streamline Health for $5.34/share, a 138% premium.

• MDaudit and Streamline Health announce merger agreement • Combined entity has over $300B in net patient revenue • MDaudit to acquire all of Streamline's outstanding shares for $5.34 per share in cash • Acquisition is a premium of 138% to Streamline's closing price on May 28, 2025 • The combined entity will provide billing compliance and revenue integrity solutions to empower health systems with actionable foresight and end-to-end visibility.

MDaudit, a leading healthcare technology provider, and Streamline Health Solutions, Inc. (Nasdaq: STRM) have entered into a definitive merger agreement. Under the terms of the agreement, MDaudit will acquire all outstanding shares of Streamline stock for $5.34 per share in cash, representing a premium of 138% to Streamline’s closing price on May 28, 2025, and a premium of 117% to its 30-day volume-weighted average stock price as of the same date [1].

The combined entity, which supports healthcare organizations nationwide with an aggregate Net Patient Revenue of more than $300B, will offer best-in-class billing compliance and revenue integrity solutions. This merger aims to empower health systems with actionable foresight and end-to-end visibility, enabling them to expand patient care and access by improving financial stability [1].

Ritesh Ramesh, CEO of MDaudit, commented, "At a time when health systems are facing mounting financial and operational pressures, we believe the future belongs to those who can connect the dots across the revenue cycle continuum with data- and AI-driven solutions. Streamline’s eValuator and RevID solutions complement MDaudit’s current strengths in billing compliance and revenue integrity capabilities by enabling pre-bill visibility in real-time to unlock revenue opportunities" [1].

Ben Stilwill, CEO of Streamline Health, added, "MDaudit and Streamline have always believed that the most sophisticated technology won’t drive successful outcomes without an unwavering focus on customer satisfaction. Our teams have built trust by being true partners to our customers. Together, we’re building a broader platform that reflects the reality of today’s revenue cycle: distributed teams, disconnected data, and immense responsibility. Together, we’re delivering foresight and action; not just reports or alerts" [1].

The transaction is valued at approximately $37.4 million, including debt, and is expected to close during the third quarter of 2025. Following the closing, Streamline’s common stock will no longer be listed on the Nasdaq Stock Market, and Streamline will become a wholly-owned subsidiary of MDaudit [1].

References:
[1] https://finance.yahoo.com/news/mdaudit-streamline-health-announce-definitive-120000128.html